FUNDING THE BEST BRAINS TO BEAT BRAIN CANCER
Dr Charlie Teo AM, Professor of Neurosurgery
Director and Founder, Charlie Teo Foundation
FUNDER PROFILE
Filmed in Sydney, Australia | December 2024
The Charlie Teo Foundation is dedicated to funding and advancing research into brain cancer, with a particular focus on developing more effective treatments and finding a cure for this devastating disease. The foundation’s mission includes:
- Supporting cutting-edge research: The foundation funds innovative research into brain cancer, aiming to discover new therapies, improve outcomes, and ultimately find a cure.
- Raising awareness: The foundation works to increase public awareness about brain cancer, its impact on patients and families, and the need for more research and funding in this field.
- Helping patients: In addition to supporting research, the foundation assists individuals and families affected by brain cancer by providing information, resources, and support.
- Advocating for change: It strives to drive systemic change in how brain cancer is researched and treated, challenging the status quo and encouraging collaboration and innovation within the medical community.
Dr. Charlie Teo AM as the Founder and Director of the Charlie Teo Foundation, has for over 30 years been instrumental in the development, dissemination and acceptance of the concept of keyhole minimally invasive techniques in neurosurgery. Dr Teo ran a fellowship program that attracts over 600 applicants yearly and has trained many of the world’s leading figures in neurosurgery. He has trained at distinguished centres such as the Barrow Neurological Institute, Johns Hopkins University, Duke University, Stanford University, Vanderbilt University and Harvard University.
Initially focused on Australia, Dr Teo recognised a pressing need to raise funds for brain cancer research from a young age. To address this, he founded the Charlie Teo Foundation in 2017, which aims to increase awareness and funding for brain cancer research.
Brain cancer significantly impacts society, being the leading cause of years of life lost. Despite its high incidence, particularly among young adults and children, it remains one of the least funded cancers. The foundation operates with low overhead costs and focuses on supporting disruptive researchers who think outside the box.
Since its inception, the foundation has committed nearly $15 million to brain cancer research, funding notable projects in Australia and the United States. These projects explore innovative approaches to understand and treat brain cancer more effectively, with a focus on translating findings from animal studies to human applications. Charlie’s dedication to finding solutions for this devastating disease remains unwavering as he travels frequently to collaborate with global researchers.
-
Paediatric haemorrhage and airway procedures
Dr Shane George is a paediatric critical care physician working in paediatric emergency medicine and paediatric intensive care at Gold Coast University Hospital. He is the clinical lead for children’s critical care research for Gold Coast Health, and is a Senior Lecturer at The University of Queensland and Griffith University.
Associate Professor George is also an active clinician researcher on topics that span both emergency medicine and PICU practice including safety in emergency intubation, sepsis, haemostatic resuscitation in children and respiratory support therapies.
-
De-prescribing medications in older adults with dementia
Dr. Daniel Hoyle is a Senior Lecturer in Therapeutics and Pharmacy Practice at the School of Pharmacy and Pharmacology, University of Tasmania. He is also an experienced clinical pharmacist with expertise in medication management in older people. Dr. Hoyle’s research interests focus on improving medicine use in older people with dementia.
-
Next-generation NK cell-based immunotherapies for hard-to-treat cancers
Associate Professor Fernando Guimaraes is an internationally recognised leader in cancer immunotherapy and natural killer (NK) cell biology. Based at The University of Queensland, he leads innovative research focused on developing next-generation NK cell-based immunotherapies for hard-to-treat cancers, including sarcomas and neuroblastoma.
